Pamidronic acid Chemical Properties

Melting point:

226-228°C

Boiling point:

658.7±65.0 °C(Predicted)

Density 

1.998±0.06 g/cm3(Predicted)

storage temp. 

under inert gas (nitrogen or Argon) at 2–8 °C

solubility 

Methanol (Very Slightly, Heated, Sonicated), Water (Slightly, Heated, Sonicated)

pka

1.44±0.10(Predicted)

form 

Solid

color 

Light Brown to Beige

Stability:

Hygroscopic

InChI

InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)

InChIKey

WRUUGTRCQOWXEG-UHFFFAOYSA-N

SMILES

C(P(=O)(O)O)(P(=O)(O)O)(O)CCN

Safety Information

HS Code 

9999999999

MSDS

• Language:English Provider:Delavirdine mesylate

Pamidronic acid Usage And Synthesis

Chemical Properties

White Solid

Originator

Aredia,Novartis,India

Uses

A biphosphonate bone resorption inhibitor.

Uses

anticancer

Definition

ChEBI: Pamidronate is a phosphonoacetic acid.

Manufacturing Process

For a batch size of 5 L, 587.5 g (3.2 moles) of mannitol is dissolved in 3.5 L of water. Pamidronic acid (31.6 g, 0.133 moles) is mixed with a 1.0 L aliquot of the mannitol solution to form a slurry. The slurry is then transferred into the remainder of the mannitol solution, and stirred for at least 15 min. Aqueous 1 N sodium hydroxide (270 ml) is then added and the mixture is stirred until a clear, colorless solution results. The pH is then adjusted to 6.50.1 using either 1 M aqueous phosphoric acid or 1 N aqueous sodium hydroxide, as needed. The solution is then filtered through a 0.22 micron filter, and filled at 20°C into vials at 4.0 ml (4.172 g)/vial, under sterile conditions. The aqueous solution is frozen at -37°C and lyophilized (20 mbar, 20°-40°C) to yield 1,250 vials, each containing 30 mg of amorphous disodium pamidronate. The vials are sealed under positive nitrogen pressure. The disodium pamidronate is amorphous (noncrystalline) by X-ray diffraction and contains 0.7 wt-% water.

brand name

Rescriptor (Agouron).

Therapeutic Function

Bone resorption suppressant

References

[1] Patent: WO2016/199111, 2016, A1. Location in patent: Paragraph 00134-00135
[2] Patent: US10081572, 2018, B2. Location in patent: Page/Page column 9
[3] Russian Journal of Bioorganic Chemistry, 2012, vol. 38, # 2, p. 224 - 229
[4] Letters in Drug Design and Discovery, 2016, vol. 13, # 6, p. 475 - 478
[5] Letters in Drug Design and Discovery, 2016, vol. 13, # 6, p. 475 - 478

Pamidronic acid (40391-99-9)Related Product Information

• Imatinib
• Lithium bis(trimethylsilyl)amide
• Stearic acid
• DELAVIRDINE
• Zoledronic acid
• Cyclamic acid
• Molasses
• Ethyl 2-(Chlorosulfonyl)acetate
• Folic acid
• N-Pentyl-β-alanine
• Citric acid
• Ascoric Acid
• Ibandronate sodium monohydrate
• Olpadronate Sodium
• methyl N-(3-methoxy-3-oxopropyl)-N-methyl-beta-alaninate
• Trisodium phosphate
• Acryloyl chloride
• N-Methylpentylamine